All treatments

Mounjaro (tirzepatide)

A prescription medicine for weight management. Whether it’s right for you is a clinical decision, made from your health information and your baseline blood test.

Available in

From £154 / month First month for new customers on a 12-month plan, at the starting dose. Everything included.

After month one: from £204 / month at the starting dose. 12-month plan total from £2,398. Full pricing by dose

Subject to clinical approval

  • Trusted by over 100k members across the UK
  • Blood tests, clinician reviews and support included
  • Next-day delivery at no charge, discreetly packaged

What Mounjaro is

Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist: a medicine that acts on two of the hormone pathways involved in appetite and blood sugar regulation. It’s made by Eli Lilly and licensed in the UK for weight management in adults.

Form

Pre-filled pen

Frequency

Once a week

Dose

Starts at 2.5mg, adjusted by your clinician

Monthly price by dose and plan

Every price includes the whole plan: the medicine, your blood tests, clinical reviews, support and delivery.

Rolling plans: cancel with at least 21 days’ notice before your next payment date. Fixed plans: cancellation terms are shown before you commit.

DoseRolling monthly3-month plan6-month plan12-month plan
2.5mg (starting dose)*£179£164£159£154
5mg£229£214£209£204
7.5mg£279£264£259£254
10mg£279£264£259£254
12.5mg£319£304£299£294
15mg£319£304£299£294

In its main clinical trial (SURMOUNT-1), adults taking tirzepatide 15mg weekly who stayed on treatment lost an average of 22.5% of their body weight over 72 weeks, compared with 2.4% for those making diet and lifestyle changes alone. Average trial results are not a prediction of individual results.1,2

In the same trial, 62.9% of people taking the 15mg dose lost 20% or more of their body weight, compared with 1.3% of those on placebo.2

*Starting-dose plan prices are first-month prices for new customers. You can cancel per the plan terms, set out before you commit.

How it compares

A factual comparison of the treatments available through the service. Which one suits you depends on your health, your history and your blood test.

Mounjaro

Weekly pen

Active ingredient
Tirzepatide
Form
Pre-filled pen, once a week
Starting dose
2.5mg

From £154 / month

This page

Wegovy

Weekly pen

Active ingredient
Semaglutide
Form
Pre-filled pen, once a week
Starting dose
0.25mg

From £59 / month

View Wegovy

Wegovy Pill

Daily tablet

Active ingredient
Semaglutide
Form
Tablet, once a day
Starting dose
1.5mg

From £69 / month

View Wegovy Pill

Foundayo

Daily tablet

Active ingredient
Orforglipron
Form
Tablet, once a day
Starting dose
0.8mg

From £69 / month

View Foundayo
WegovyWeekly penWegovy PillDaily tabletMounjaroWeekly penFoundayoDaily tablet
Active ingredientSemaglutideSemaglutideTirzepatideOrforglipron
FormPre-filled pen, once a weekTablet, once a dayPre-filled pen, once a weekTablet, once a day
Starting dose0.25mg1.5mg2.5mg0.8mg
Average weight loss in its main trial*18.7% (7.2mg, STEP UP, 72 weeks)13.6% (25mg, OASIS 4, 64 weeks)20.9% (15mg, SURMOUNT-1, 72 weeks)11.2% (highest trial dose, ATTAIN-1, 72 weeks)
From£59 / month£69 / month£154 / month£69 / month
View WegovyView Wegovy PillThis pageView Foundayo

*Averages from each medicine's own main trial on its main analysis: separate trials with different designs and durations, not head-to-head comparisons, and not a prediction for any one person. Placebo groups lost 2.2% to 3.9% across these trials. Each medicine's page carries its fuller results and sources.

Who may be eligible

Always a clinical decision: a clinician reviews your blood test and health information before prescribing anything.

May be considered

  • Adults with a BMI of 30 or over
  • Adults with a BMI of 27 or over alongside a weight-related health condition

Not suitable

  • In pregnancy, or when trying to conceive
  • Under 18
  • With certain medical histories: the clinician screens for these, and the patient information leaflet carries the full list

Side effects

The most commonly reported side effects are digestive: nausea, diarrhoea, constipation and vomiting, most often while the dose is increasing. The patient information leaflet carries the full list, including rarer serious side effects and when to seek urgent help: read it before starting. Your clinician reviews side effects with you during care, and you can report them through the MHRA Yellow Card scheme.

Questions, asked and answered

Is Mounjaro available through HeMed?

Yes, where a clinician judges it appropriate. Mounjaro is one of four treatments available through the service; the clinical review and your blood test decide what’s recommended.

How much does Mounjaro cost?

From £154 a month for new customers on a 12-month plan at the starting dose. The table above lists every dose and plan; every price includes the whole plan.

Do I need a prescription?

Yes. Mounjaro is a prescription-only medicine. A clinician reviews your health information and blood test, and prescribes only if treatment is appropriate.

Can I change treatment later?

Yes, if it’s clinically right for you. Your clinician can reassess your plan at any review.

Sources

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022;387(3):205-216. doi.org/10.1056/NEJMoa2206038.
  2. Mounjaro KwikPen, Summary of Product Characteristics. Eli Lilly and Company Limited. medicines.org.uk/emc/product/15486/smpc. Accessed 7 September 2026.
  3. Comparison table trial figures (main-analysis averages; separate trials): STEP UP doi.org/10.1016/S2213-8587(25)00226-8; SURMOUNT-1 doi.org/10.1056/NEJMoa2206038; OASIS 4 doi.org/10.1056/NEJMoa2500969; ATTAIN-1 doi.org/10.1056/NEJMoa2511774.

See where you stand

The eligibility check takes a few minutes. Every plan starts with a blood test, so the decisions come from your numbers.

Check your eligibility